Excellent presentation by our PhD candidate @lauritzen_trine at #ESCPrev2024
✅ The first study evaluating mevalonate in blood and muscle as potential biomarker of statin intolerance
@ntvethe@VestreViken
Excellent presentation by our PhD candidate @Jonaspivoriunas at #ESCPrev2024
✅ statin adherence measured with our novel blood test strongly aligns with long-term adherence assessed by pharmacy registry. The blood test emerges as a promising tool for enhancing lipid management
Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Clopidogrel on Ischemic Outcomes After PCI https://t.co/sKMsCltPE4 via @JAMA_current part of @JAMANetwork
Encephalopathy and coma developed in a 13-year-old boy shortly after he received a single dose of ivermectin to prevent scabies infection. ABCB1 sequencing identified the child as a compound heterozygote for two nonsense mutations.
Emerging evidence suggests that optimal lipid lowering therapy produces the greatest absolute reduction in apoB. Because 90% of circulating apoB particles are LDL, therapy that reduces LDL-C (eg #statins) are optimal first therapy for most people https://t.co/ejopqWVKqL
Atorvastatin does not affect the intensity of muscle symptoms in patients with self-perceived SAMS: results from a randomized trial. https://t.co/k0FvwXSTw1
#cardiotwitter#EHJPharmacotherapy@AgewallStefan